Chul Kim

CEO at Progeneer

Presenter

Chul Kim, M.D., Ph.D. Chief Executive Officer, Progeneer Inc.

Dr. Chul Kim is a board-certified medical oncologist and holds a Ph.D. in Pharmacology. He has more than 20 years of experience in research and clinical development in the biopharmaceutical industry and currently serves as the Chief Executive Officer of Progeneer Inc.

Prior to joining Progeneer, Dr. Kim led numerous clinical development projects at global pharmaceutical and biotechnology companies and research institutions, where he gained extensive experience in the clinical development of novel therapeutics and biosimilars, as well as in development strategy.

Since joining Progeneer in 2021, Dr. Kim has been leading the development of the company's proprietary TLR7/8-based adjuvant platform, ProLNG, and its personalized cancer vaccine, ProV-001. Under his leadership, Progeneer has established a global patent portfolio and has actively pursued collaborations and business development opportunities with biotechnology companies across the United States, Europe, and Asia.

Previous Positions

Board-Certified Medical Oncologist Head of Clinical Medicine, Samsung Bioepis National Cancer Center, Republic of Korea Department of Medical Oncology, Asan Medical Center, Seoul Medical Director, Schering-Plough Head of Medical Affairs, Novartis